Novo Drug Patent Portfolio
Novo owns 11 orange book drugs protected by 82 US patents with Fiasp having the least patent protection, holding only 1 patent. And Saxenda with maximum patent protection, holding 48 patents. Given below is the list of Novo's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11318191 | GLP-1 compositions and uses thereof | 17 Feb, 2041 | Active |
| US11833248 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | 01 Feb, 2039 | Active |
| US11286488 | Methods and compositions for inhibiting expression of LDHA | 12 Oct, 2038 | Active |
| US11661604 | Methods and compositions for inhibiting expression of LDHA | 12 Oct, 2038 | Active |
| US12029779 | Semaglutide in medical therapy | 10 Oct, 2038 | Active |
| US10888605 | GLP-1 compositions and uses thereof | 24 Aug, 2038 | Active |
| US11752198 | GLP-1 compositions and uses thereof | 24 Aug, 2038 | Active |
| US12214017 | GLP-1 compositions and uses thereof | 24 Aug, 2038 | Active |
| US9968659 | Liraglutide in cardiovascular conditions | 09 Jul, 2037 | Active |
| US9968659 | Liraglutide in cardiovascular conditions | 09 Jan, 2037 | Active |
| US11053502 | Therapeutic inhibition of lactate dehydrogenase and agents therefor | 29 Oct, 2035 | Active |
| US10351854 | Therapeutic inhibition of lactate dehydrogenase and agents therefor | 09 Oct, 2035 | Active |
| US10738311 | Therapeutic inhibition of lactate dehydrogenase and agents therefor | 09 Oct, 2035 | Active |
| US11359203 | Therapeutic inhibition of lactate dehydrogenase and agents therefor | 09 Oct, 2035 | Active |
| US10278923 | Oral dosing of GLP-1 compounds | 02 May, 2034 | Active |
| US10335462 | Use of long-acting GLP-1 peptides | 21 Jun, 2033 | Active |
| US9764003 | Use of long-acting GLP-1 peptides | 21 Jun, 2033 | Active |
| US9884094 | Method of treating diabetes mellitus | 01 May, 2033 | Active |
| US10933120 | Compositions of GLP-1 peptides and preparation thereof | 15 Mar, 2033 | Active |
| US11759501 | Compositions of GLP-1 peptides and preparation thereof | 15 Mar, 2033 | Active |
| US11759502 | Compositions of GLP-1 peptides and preparation thereof | 15 Mar, 2033 | Active |
| US11759503 | Compositions of GLP-1 peptides and preparation thereof | 15 Mar, 2033 | Active |
| US9132239 | Dial-down mechanism for wind-up pen | 01 Aug, 2032 | Active |
| US9132239 | Dial-down mechanism for wind-up pen | 01 Feb, 2032 | Active |
| US10086047 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | 16 Dec, 2031 | Active |
| US10960052 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid | 16 Dec, 2031 | Active |
| US11382957 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | 16 Dec, 2031 | Active |
| US9278123 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | 16 Dec, 2031 | Active |
| US8129343 | Acylated GLP-1 compounds | 05 Dec, 2031 | Active |
| US8324157 | Preparation comprising insulin, nicotinamide and an amino acid | 25 Jun, 2030 | Active |
| US7615532 | Insulin derivatives | 28 Dec, 2029 | Active |
| US8937042 | Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide | 05 Nov, 2029 | Active |
| US7615532 | Insulin derivatives | 28 Jun, 2029 | Active |
| US8937042 | Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide | 05 May, 2029 | Active |
| US9457154 | Injection device with an end of dose feedback mechanism | 27 Mar, 2028 | Active |
| US8192719 | Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds | 12 Oct, 2027 | Active |
| US9457154 | Injection device with an end of dose feedback mechanism | 27 Sep, 2027 | Active |
| US9687611 | Injection device with torsion spring and rotatable display | 27 Aug, 2027 | Active |
| US9687611 | Injection device with torsion spring and rotatable display | 27 Feb, 2027 | Active |
| USRE46363 | Dial-down mechanism for wind-up pen | 03 Feb, 2027 | Active |
| US10220155 | Syringe device with a dose limiting mechanism and an additional safety mechanism | 17 Jan, 2027 | Active |
| US8920383 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left | 17 Jan, 2027 | Active |
| US9775953 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left | 17 Jan, 2027 | Active |
| US7686786 | Dial-down mechanism for wind-up pen | 03 Aug, 2026 | Active |
| USRE46363 | Dial-down mechanism for wind-up pen | 03 Aug, 2026 | Active |
| US9108002 | Automatic injection device with a top release mechanism | 20 Jul, 2026 | Active |
| US9616180 | Automatic injection device with a top release mechanism | 20 Jul, 2026 | Active |
| US9861757 | Injection device with an end of dose feedback mechanism | 20 Jul, 2026 | Active |
| US10220155 | Syringe device with a dose limiting mechanism and an additional safety mechanism | 17 Jul, 2026 | Active |
| US8920383 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left | 17 Jul, 2026 | Active |
| US9775953 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left | 17 Jul, 2026 | Active |
| US11097063 | Syringe device with a dose limiting mechanism and an additional safety mechanism | 17 Jul, 2026 | Active |
| US8684969 | Injection device with torsion spring and rotatable display | 20 Apr, 2026 | Active |
| US8536122 | Acylated GLP-1 compounds | 20 Mar, 2026 | Active |
| US8114833 | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices | 13 Feb, 2026 | Active |
| US10357616 | Injection device with an end of dose feedback mechanism | 20 Jan, 2026 | Active |
| US10376652 | Automatic injection device with a top release mechanism | 20 Jan, 2026 | Active |
| US9108002 | Automatic injection device with a top release mechanism | 20 Jan, 2026 | Active |
| US9616180 | Automatic injection device with a top release mechanism | 20 Jan, 2026 | Active |
| US9861757 | Injection device with an end of dose feedback mechanism | 20 Jan, 2026 | Active |
| US11311679 | Automatic injection device with a top release mechanism | 20 Jan, 2026 | Active |
| US8684969 | Injection device with torsion spring and rotatable display | 20 Oct, 2025 | Active |
| US11446443 | Injection device with torsion spring and rotatable display | 20 Oct, 2025 | Active |
| US8114833 | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices | 13 Aug, 2025 | Active |
| US7762994 | Needle mounting system and a method for mounting a needle assembly | 23 Nov, 2024 | Expired |
| US7762994 | Needle mounting system and a method for mounting a needle assembly | 23 May, 2024 | Expired |
| US8579869 | Needle mounting system and a method for mounting a needle assembly | 30 Dec, 2023 | Expired |
| US8579869 | Needle mounting system and a method for mounting a needle assembly | 30 Jun, 2023 | Expired |
| US6268343 | Derivatives of GLP-1 analogs | 22 Feb, 2023 | Expired |
| US8846618 | Stable formulation of modified GLP-1 | 27 Dec, 2022 | Expired |
| US6268343 | Derivatives of GLP-1 analogs | 22 Aug, 2022 | Expired |
| US6861409 | Growth hormone secretagogues | 01 Aug, 2022 | Expired |
| US6899699 | Automatic injection device with reset feature | 02 Jul, 2022 | Expired |
| US8672898 | Automatic injection device with reset feature | 02 Jul, 2022 | Expired |
| US9486588 | Automatic injection device with reset feature | 02 Jul, 2022 | Expired |
| US8846618 | Stable formulation of modified GLP-1 | 27 Jun, 2022 | Expired |
| US6899699 | Automatic injection device with reset feature | 02 Jan, 2022 | Expired |
| US8672898 | Automatic injection device with reset feature | 02 Jan, 2022 | Expired |
| US9486588 | Automatic injection device with reset feature | 02 Jan, 2022 | Expired |
| US6458924 | Derivatives of GLP-1 analogs | 22 Aug, 2017 | Expired |
| US7235627 | Derivatives of GLP-1 analogs | 22 Aug, 2017 | Expired |
| US5866538 | Insulin preparations containing NaCl | 20 Jun, 2017 | Expired |
Latest Legal Activities on Novo's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Novo.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Email Notification
Critical
| 16 Jul, 2024 | US11286488 |
| Recordation of Patent eCertificate of Correction | 16 Jul, 2024 | US11286488 |
| Patent eCofC Notification | 16 Jul, 2024 | US11286488 |
| Mail Patent eCofC Notification | 16 Jul, 2024 | US11286488 |
| Post Issue Communication - Certificate of Correction | 12 Jul, 2024 | US11661604 |
| Mail Pub Notice re 312 amendment | 01 Jul, 2024 | US11661604 |
|
Email Notification
Critical
| 01 Jul, 2024 | US11661604 |
|
Maintenance Fee Reminder Mailed
Critical
| 01 Jul, 2024 | US9486588 |
|
Maintenance Fee Reminder Mailed
Critical
| 01 Jul, 2024 | US9486588 |
| Post Issue Communication - Certificate of Correction Denied | 26 Jun, 2024 | US11661604 |
| POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION | 26 Jun, 2024 | US11661604 |
| Post Issue Communication - Certificate of Correction | 25 Jun, 2024 | US11286488 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Jun, 2024 | US10888605 (Litigated) |
| Mail Pub Notice re 312 amendment | 11 Jun, 2024 | US11661604 |
|
Email Notification
Critical
| 11 Jun, 2024 | US11661604 |
Novo's Drug Patent Litigations
Novo's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 22, 2020, against patent number US8114833. The petitioner Pfizer Inc., challenged the validity of this patent, with Novo Nordisk A/S as the respondent. Click below to track the latest information on how companies are challenging Novo's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US10335462 | March, 2024 | Pending | Novo Nordisk A/S | Apotex Inc. et al. |
| US10335462 | November, 2023 |
Trial Instituted
(28 May, 2024)
| Novo Nordisk A/S | Sun Pharmaceutical Industries Ltd. et al. |
| US10335462 | October, 2023 |
Trial Instituted
(25 Apr, 2024)
| Novo Nordisk A/S | DR. REDDY'S LABORATORIES, INC. et al. |
| US10335462 | March, 2023 |
Trial Instituted
(04 Oct, 2023)
| Novo Nordisk A/S | Mylan Pharmaceuticals Inc. et al. |
| US8129343 | March, 2023 |
Institution Denied
(02 Oct, 2023)
| Novo Nordisk A/S | Mylan Pharmaceuticals Inc. et al. |
| US8536122 | March, 2023 |
Institution Denied
(02 Oct, 2023)
| Novo Nordisk A/S | Mylan Pharmaceuticals Inc. et al. |
| US8114833 | March, 2022 |
Terminated-Settled
(08 Sep, 2022)
| Novo Nordisk A/S | Fresenius Kabi USA, LLC |
| US8114833 | December, 2019 |
Terminated-Settled
(21 Jun, 2021)
| Novo Nordisk A/S et al. | Pfizer Inc. et al. |
| US8114833 | July, 2020 |
Terminated-Settled
(21 Jun, 2021)
| Novo Nordisk A/S | Pfizer Inc. |
Novo Drug Patents' Oppositions Filed in EPO
Novo drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 23, 2006, by Owen Mumford Limited. This opposition was filed on patent number EP02726984A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP02726984A | NA | Genentech, Inc. | Patent maintained as amended |
| EP17710160A | May, 2022 | Dr. Schön, Neymeyr & Partner Patentanwälte mbB | Granted and Under Opposition |
| EP17710160A | May, 2022 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP17710160A | May, 2022 | SANDOZ AG | Granted and Under Opposition |
| EP17710160A | May, 2022 | Adalvo Ltd. | Granted and Under Opposition |
| EP17710160A | Apr, 2022 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP13737808A | Jan, 2021 | Galenicum Health S.L.U. | Granted and Under Opposition |
| EP13737808A | Jan, 2021 | Teva Pharmaceutical Industries LTD. | Granted and Under Opposition |
| EP13737808A | Jan, 2021 | Generics [UK] Limited | Granted and Under Opposition |
| EP17204363A | Dec, 2020 | Galenicum Health S.L.U. | Granted and Under Opposition |
| EP17204363A | Dec, 2020 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP17204363A | Dec, 2020 | Hexal AG | Granted and Under Opposition |
| EP17204363A | Dec, 2020 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP17196501A | Dec, 2019 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP17196501A | Dec, 2019 | Hoffmann Eitle | Granted and Under Opposition |
| EP17196501A | Dec, 2019 | Dr. Reddy's Laboratories Limited | Granted and Under Opposition |
| EP17196501A | Dec, 2019 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP17196501A | Dec, 2019 | Galenicum Health S.L.U. | Granted and Under Opposition |
| EP13709231A | May, 2019 | Galenicum Health S.L.U. | Granted and Under Opposition |
| EP14721834A | May, 2019 | Sanofi | Granted and Under Opposition |
| EP14721834A | May, 2019 | Hexal AG | Granted and Under Opposition |
| EP14721834A | May, 2019 | Galenicum Health S.L.U. | Granted and Under Opposition |
| EP14721834A | May, 2019 | Lederer & Keller Patentanwälte Partnerschaft mbB | Granted and Under Opposition |
| EP14721834A | May, 2019 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP13709231A | May, 2019 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP13709231A | May, 2019 | Hexal AG | Granted and Under Opposition |
| EP14721834A | May, 2019 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP13709231A | May, 2019 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP11805824A | Sep, 2018 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP11805824A | Sep, 2018 | Galenicum Health S.L. | Granted and Under Opposition |
| EP11805824A | Sep, 2018 | Hexal AG | Granted and Under Opposition |
| EP11805824A | Sep, 2018 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP04797453A | Aug, 2018 | Uexküll & Stolberg Partnerschaft von Patent- und Rechtsanwälten mbB | Opposition rejected |
| EP04797453A | Aug, 2018 | Generics (U.K.) Limited | Opposition rejected |
| EP04797453A | Aug, 2018 | Teva Pharmaceutical Industries Ltd | Opposition rejected |
| EP04797453A | Aug, 2018 | Wittkopp, Alexander | Opposition rejected |
| EP04797453A | Aug, 2018 | Sandoz AG | Opposition rejected |
| EP04797453A | Aug, 2018 | Fresenius Kabi Deutschland GmbH | Opposition rejected |
| EP06701034A | Jan, 2018 | Schwöbel, Thilo | Opposition rejected |
| EP06754730A | Dec, 2011 | Ypsomed AG | Patent maintained as amended |
| EP06754730A | Nov, 2011 | WMC Matthes Consulting | Patent maintained as amended |
| EP06725149A | May, 2011 | AMYLIN PHARMACEUTICALS, INC. | Opposition rejected |
| EP06762643A | Jul, 2010 | Sanofi-Aventis Deutschland GmbH | Patent maintained as amended |
| EP05796880A | Jul, 2010 | Stöckeler, Ferdinand | Granted and Under Opposition |
| EP05796880A | Jul, 2010 | Ypsomed AG | Granted and Under Opposition |
| EP05796880A | Jul, 2010 | OWEN MUMFORD LIMITED | Granted and Under Opposition |
| EP05796880A | Jul, 2010 | Ferring International Center S.A. | Granted and Under Opposition |
| EP05796880A | Jul, 2010 | COPERNICUS sp. zo.o. | Granted and Under Opposition |
| EP05796880A | Jul, 2010 | Genentech, Inc. | Granted and Under Opposition |
| EP06121820A | May, 2010 | SANOFI-AVENTIS DEUTSCHLAND GMBH | Opposition rejected |
| EP02745182A | Sep, 2008 | AMYLIN PHARMACEUTICALS, INC. | Opposition rejected |
| EP02726984A | Mar, 2006 | TecPharma Licensing AG | Patent maintained as amended |
| EP02726984A | Feb, 2006 | OWEN MUMFORD LIMITED | Patent maintained as amended |
Novo's Family Patents
Novo drugs have patent protection in a total of 44 countries. It's US patent count contributes only to 17.2% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Novo Drug List
Given below is the complete list of Novo's drugs and the patents protecting them.
1. Fiasp
Fiasp is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8324157 | Preparation comprising insulin, nicotinamide and an amino acid |
25 Jun, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fiasp's drug page
2. Fiasp Flextouch
Fiasp Flextouch is protected by 20 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9132239 | Dial-down mechanism for wind-up pen |
01 Feb, 2032
(6 years from now)
| Active |
| US8324157 | Preparation comprising insulin, nicotinamide and an amino acid |
25 Jun, 2030
(5 years from now)
| Active |
| US9687611 | Injection device with torsion spring and rotatable display |
27 Feb, 2027
(1 year, 9 months from now)
| Active |
| US7686786 | Dial-down mechanism for wind-up pen |
03 Aug, 2026
(1 year, 2 months from now)
| Active |
| USRE46363 | Dial-down mechanism for wind-up pen |
03 Aug, 2026
(1 year, 2 months from now)
| Active |
| US10220155 | Syringe device with a dose limiting mechanism and an additional safety mechanism |
17 Jul, 2026
(1 year, 2 months from now)
| Active |
| US8920383 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
17 Jul, 2026
(1 year, 2 months from now)
| Active |
| US9775953 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
17 Jul, 2026
(1 year, 2 months from now)
| Active |
| US10357616 | Injection device with an end of dose feedback mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US10376652 | Automatic injection device with a top release mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US9108002 | Automatic injection device with a top release mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US9457154 | Injection device with an end of dose feedback mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US9616180 | Automatic injection device with a top release mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US9861757 | Injection device with an end of dose feedback mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US8684969 | Injection device with torsion spring and rotatable display |
20 Oct, 2025
(5 months from now)
| Active |
| US7762994 | Needle mounting system and a method for mounting a needle assembly |
23 May, 2024
(11 months ago)
| Expired |
| US8579869 | Needle mounting system and a method for mounting a needle assembly |
30 Jun, 2023
(1 year, 10 months ago)
| Expired |
| US6899699 | Automatic injection device with reset feature |
02 Jan, 2022
(3 years ago)
| Expired |
| US8672898 | Automatic injection device with reset feature |
02 Jan, 2022
(3 years ago)
| Expired |
| US9486588 | Automatic injection device with reset feature |
02 Jan, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fiasp Flextouch's drug page
3. Macrilen
Macrilen is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8192719 | Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds |
12 Oct, 2027
(2 years from now)
| Active |
| US6861409 | Growth hormone secretagogues |
01 Aug, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Macrilen's drug page
4. Ozempic
Ozempic is protected by 26 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10335462 | Use of long-acting GLP-1 peptides |
21 Jun, 2033
(8 years from now)
| Active |
| US9132239 | Dial-down mechanism for wind-up pen |
01 Feb, 2032
(6 years from now)
| Active |
| US8129343 | Acylated GLP-1 compounds |
05 Dec, 2031
(6 years from now)
| Active |
| US9457154 | Injection device with an end of dose feedback mechanism |
29 Sep, 2027
(2 years from now)
| Active |
| US9457154 | Injection device with an end of dose feedback mechanism |
27 Sep, 2027
(2 years from now)
| Active |
| US9687611 | Injection device with torsion spring and rotatable display |
27 Feb, 2027
(1 year, 9 months from now)
| Active |
| USRE46363 | Dial-down mechanism for wind-up pen |
03 Aug, 2026
(1 year, 2 months from now)
| Active |
| US10220155 | Syringe device with a dose limiting mechanism and an additional safety mechanism |
17 Jul, 2026
(1 year, 2 months from now)
| Active |
| US11097063 | Syringe device with a dose limiting mechanism and an additional safety mechanism |
17 Jul, 2026
(1 year, 2 months from now)
| Active |
| US8920383 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
17 Jul, 2026
(1 year, 2 months from now)
| Active |
| US9775953 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
17 Jul, 2026
(1 year, 2 months from now)
| Active |
| US8536122 | Acylated GLP-1 compounds |
20 Mar, 2026
(10 months from now)
| Active |
| US10357616 | Injection device with an end of dose feedback mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US10376652 | Automatic injection device with a top release mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US11311679 | Automatic injection device with a top release mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US9108002 | Automatic injection device with a top release mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US9616180 | Automatic injection device with a top release mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US9861757 | Injection device with an end of dose feedback mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US11446443 | Injection device with torsion spring and rotatable display |
20 Oct, 2025
(5 months from now)
| Active |
| US8684969 | Injection device with torsion spring and rotatable display |
20 Oct, 2025
(5 months from now)
| Active |
| US8114833 | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
13 Aug, 2025
(3 months from now)
| Active |
| US7762994 | Needle mounting system and a method for mounting a needle assembly |
23 May, 2024
(11 months ago)
| Expired |
| US8579869 | Needle mounting system and a method for mounting a needle assembly |
30 Jun, 2023
(1 year, 10 months ago)
| Expired |
| US6899699 | Automatic injection device with reset feature |
02 Jan, 2022
(3 years ago)
| Expired |
| US8672898 | Automatic injection device with reset feature |
02 Jan, 2022
(3 years ago)
| Expired |
| US9486588 | Automatic injection device with reset feature |
02 Jan, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ozempic's drug page
5. Rivfloza
Rivfloza is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11286488 | Methods and compositions for inhibiting expression of LDHA |
12 Oct, 2038
(13 years from now)
| Active |
| US11661604 | Methods and compositions for inhibiting expression of LDHA |
12 Oct, 2038
(13 years from now)
| Active |
| US11053502 | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
29 Oct, 2035
(10 years from now)
| Active |
| US10351854 | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
09 Oct, 2035
(10 years from now)
| Active |
| US10738311 | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
09 Oct, 2035
(10 years from now)
| Active |
| US11359203 | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
09 Oct, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rivfloza's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Rybelsus
Rybelsus is protected by 12 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11833248 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
01 Feb, 2039
(13 years from now)
| Active |
| US10278923 | Oral dosing of GLP-1 compounds |
02 May, 2034
(8 years from now)
| Active |
| US10933120 | Compositions of GLP-1 peptides and preparation thereof |
15 Mar, 2033
(7 years from now)
| Active |
| US11759501 | Compositions of GLP-1 peptides and preparation thereof |
15 Mar, 2033
(7 years from now)
| Active |
| US11759502 | Compositions of GLP-1 peptides and preparation thereof |
15 Mar, 2033
(7 years from now)
| Active |
| US11759503 | Compositions of GLP-1 peptides and preparation thereof |
15 Mar, 2033
(7 years from now)
| Active |
| US10086047 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
16 Dec, 2031
(6 years from now)
| Active |
| US10960052 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid |
16 Dec, 2031
(6 years from now)
| Active |
| US11382957 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
16 Dec, 2031
(6 years from now)
| Active |
| US9278123 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
16 Dec, 2031
(6 years from now)
| Active |
| US8129343 | Acylated GLP-1 compounds |
05 Dec, 2031
(6 years from now)
| Active |
| US8536122 | Acylated GLP-1 compounds |
20 Mar, 2026
(10 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rybelsus's drug page
7. Ryzodeg 70/30
Ryzodeg 70/30 is protected by 22 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9884094 | Method of treating diabetes mellitus |
01 May, 2033
(7 years from now)
| Active |
| US9132239 | Dial-down mechanism for wind-up pen |
01 Feb, 2032
(6 years from now)
| Active |
| US7615532 | Insulin derivatives |
28 Jun, 2029
(4 years from now)
| Active |
| US9457154 | Injection device with an end of dose feedback mechanism |
27 Sep, 2027
(2 years from now)
| Active |
| US9687611 | Injection device with torsion spring and rotatable display |
27 Feb, 2027
(1 year, 9 months from now)
| Active |
| US7686786 | Dial-down mechanism for wind-up pen |
03 Aug, 2026
(1 year, 2 months from now)
| Active |
| USRE46363 | Dial-down mechanism for wind-up pen |
03 Aug, 2026
(1 year, 2 months from now)
| Active |
| US10220155 | Syringe device with a dose limiting mechanism and an additional safety mechanism |
17 Jul, 2026
(1 year, 2 months from now)
| Active |
| US8920383 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
17 Jul, 2026
(1 year, 2 months from now)
| Active |
| US9775953 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
17 Jul, 2026
(1 year, 2 months from now)
| Active |
| US10357616 | Injection device with an end of dose feedback mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US10376652 | Automatic injection device with a top release mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US9108002 | Automatic injection device with a top release mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US9616180 | Automatic injection device with a top release mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US9861757 | Injection device with an end of dose feedback mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US8684969 | Injection device with torsion spring and rotatable display |
20 Oct, 2025
(5 months from now)
| Active |
| US7762994 | Needle mounting system and a method for mounting a needle assembly |
23 May, 2024
(11 months ago)
| Expired |
| US8579869 | Needle mounting system and a method for mounting a needle assembly |
30 Jun, 2023
(1 year, 10 months ago)
| Expired |
| US6899699 | Automatic injection device with reset feature |
02 Jan, 2022
(3 years ago)
| Expired |
| US8672898 | Automatic injection device with reset feature |
02 Jan, 2022
(3 years ago)
| Expired |
| US9486588 | Automatic injection device with reset feature |
02 Jan, 2022
(3 years ago)
| Expired |
| US5866538 | Insulin preparations containing NaCl |
20 Jun, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ryzodeg 70/30's drug page
8. Saxenda
Saxenda is protected by 48 patents, out of which 16 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9968659
(Pediatric)
| Liraglutide in cardiovascular conditions |
09 Jul, 2037
(12 years from now)
| Active |
| US9968659 | Liraglutide in cardiovascular conditions |
09 Jan, 2037
(11 years from now)
| Active |
| US9132239
(Pediatric)
| Dial-down mechanism for wind-up pen |
01 Aug, 2032
(7 years from now)
| Active |
| US9132239 | Dial-down mechanism for wind-up pen |
01 Feb, 2032
(6 years from now)
| Active |
| US9457154
(Pediatric)
| Injection device with an end of dose feedback mechanism |
27 Mar, 2028
(2 years from now)
| Active |
| US9457154 | Injection device with an end of dose feedback mechanism |
27 Sep, 2027
(2 years from now)
| Active |
| US9687611
(Pediatric)
| Injection device with torsion spring and rotatable display |
27 Aug, 2027
(2 years from now)
| Active |
| US9687611 | Injection device with torsion spring and rotatable display |
27 Feb, 2027
(1 year, 9 months from now)
| Active |
| USRE46363
(Pediatric)
| Dial-down mechanism for wind-up pen |
03 Feb, 2027
(1 year, 8 months from now)
| Active |
| US10220155
(Pediatric)
| Syringe device with a dose limiting mechanism and an additional safety mechanism |
17 Jan, 2027
(1 year, 8 months from now)
| Active |
| US8920383
(Pediatric)
| Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
17 Jan, 2027
(1 year, 8 months from now)
| Active |
| US9775953
(Pediatric)
| Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
17 Jan, 2027
(1 year, 8 months from now)
| Active |
| US7686786 | Dial-down mechanism for wind-up pen |
03 Aug, 2026
(1 year, 2 months from now)
| Active |
| USRE46363 | Dial-down mechanism for wind-up pen |
03 Aug, 2026
(1 year, 2 months from now)
| Active |
| US9108002
(Pediatric)
| Automatic injection device with a top release mechanism |
26 Jul, 2026
(1 year, 2 months from now)
| Active |
| US9616180
(Pediatric)
| Automatic injection device with a top release mechanism |
20 Jul, 2026
(1 year, 2 months from now)
| Active |
| US9861757
(Pediatric)
| Injection device with an end of dose feedback mechanism |
20 Jul, 2026
(1 year, 2 months from now)
| Active |
| US10220155 | Syringe device with a dose limiting mechanism and an additional safety mechanism |
17 Jul, 2026
(1 year, 2 months from now)
| Active |
| US11097063 | Syringe device with a dose limiting mechanism and an additional safety mechanism |
17 Jul, 2026
(1 year, 2 months from now)
| Active |
| US8920383 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
17 Jul, 2026
(1 year, 2 months from now)
| Active |
| US9775953 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
17 Jul, 2026
(1 year, 2 months from now)
| Active |
| US8684969
(Pediatric)
| Injection device with torsion spring and rotatable display |
20 Apr, 2026
(11 months from now)
| Active |
| US8114833
(Pediatric)
| Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
13 Feb, 2026
(9 months from now)
| Active |
| US9108002 | Automatic injection device with a top release mechanism |
26 Jan, 2026
(8 months from now)
| Active |
| US10357616 | Injection device with an end of dose feedback mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US10376652 | Automatic injection device with a top release mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US11311679 | Automatic injection device with a top release mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US9616180 | Automatic injection device with a top release mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US9861757 | Injection device with an end of dose feedback mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US11446443 | Injection device with torsion spring and rotatable display |
20 Oct, 2025
(5 months from now)
| Active |
| US8684969 | Injection device with torsion spring and rotatable display |
20 Oct, 2025
(5 months from now)
| Active |
| US8114833 | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
13 Aug, 2025
(3 months from now)
| Active |
| US7762994
(Pediatric)
| Needle mounting system and a method for mounting a needle assembly |
23 Nov, 2024
(5 months ago)
| Expired |
| US7762994 | Needle mounting system and a method for mounting a needle assembly |
23 May, 2024
(11 months ago)
| Expired |
| US8579869
(Pediatric)
| Needle mounting system and a method for mounting a needle assembly |
30 Dec, 2023
(1 year, 4 months ago)
| Expired |
| US8579869 | Needle mounting system and a method for mounting a needle assembly |
30 Jun, 2023
(1 year, 10 months ago)
| Expired |
| US6268343
(Pediatric)
| Derivatives of GLP-1 analogs |
22 Feb, 2023
(2 years ago)
| Expired |
| US8846618
(Pediatric)
| Stable formulation of modified GLP-1 |
27 Dec, 2022
(2 years ago)
| Expired |
| US6268343 | Derivatives of GLP-1 analogs |
22 Aug, 2022
(2 years ago)
| Expired |
| US8672898
(Pediatric)
| Automatic injection device with reset feature |
02 Jul, 2022
(2 years ago)
| Expired |
| US9486588
(Pediatric)
| Automatic injection device with reset feature |
02 Jul, 2022
(2 years ago)
| Expired |
| US6899699
(Pediatric)
| Automatic injection device with reset feature |
01 Jul, 2022
(2 years ago)
| Expired |
| US8846618 | Stable formulation of modified GLP-1 |
27 Jun, 2022
(2 years ago)
| Expired |
| US8672898 | Automatic injection device with reset feature |
02 Jan, 2022
(3 years ago)
| Expired |
| US9486588 | Automatic injection device with reset feature |
02 Jan, 2022
(3 years ago)
| Expired |
| US6899699 | Automatic injection device with reset feature |
01 Jan, 2022
(3 years ago)
| Expired |
| US6458924 | Derivatives of GLP-1 analogs |
22 Aug, 2017
(7 years ago)
| Expired |
| US7235627 | Derivatives of GLP-1 analogs |
22 Aug, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Saxenda's drug page
9. Tresiba
Tresiba is protected by 20 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9132239 | Dial-down mechanism for wind-up pen |
01 Feb, 2032
(6 years from now)
| Active |
| US7615532 | Insulin derivatives |
28 Jun, 2029
(4 years from now)
| Active |
| US9457154 | Injection device with an end of dose feedback mechanism |
27 Sep, 2027
(2 years from now)
| Active |
| US9687611 | Injection device with torsion spring and rotatable display |
27 Feb, 2027
(1 year, 9 months from now)
| Active |
| US7686786 | Dial-down mechanism for wind-up pen |
03 Aug, 2026
(1 year, 2 months from now)
| Active |
| USRE46363 | Dial-down mechanism for wind-up pen |
03 Aug, 2026
(1 year, 2 months from now)
| Active |
| US10220155 | Syringe device with a dose limiting mechanism and an additional safety mechanism |
17 Jul, 2026
(1 year, 2 months from now)
| Active |
| US8920383 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
17 Jul, 2026
(1 year, 2 months from now)
| Active |
| US9775953 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
17 Jul, 2026
(1 year, 2 months from now)
| Active |
| US10357616 | Injection device with an end of dose feedback mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US10376652 | Automatic injection device with a top release mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US9108002 | Automatic injection device with a top release mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US9616180 | Automatic injection device with a top release mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US9861757 | Injection device with an end of dose feedback mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US8684969 | Injection device with torsion spring and rotatable display |
20 Oct, 2025
(5 months from now)
| Active |
| US7762994 | Needle mounting system and a method for mounting a needle assembly |
23 May, 2024
(11 months ago)
| Expired |
| US8579869 | Needle mounting system and a method for mounting a needle assembly |
30 Jun, 2023
(1 year, 10 months ago)
| Expired |
| US6899699 | Automatic injection device with reset feature |
02 Jan, 2022
(3 years ago)
| Expired |
| US8672898 | Automatic injection device with reset feature |
02 Jan, 2022
(3 years ago)
| Expired |
| US9486588 | Automatic injection device with reset feature |
02 Jan, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tresiba's drug page
10. Wegovy
Wegovy is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11318191 | GLP-1 compositions and uses thereof |
17 Feb, 2041
(15 years from now)
| Active |
| US12029779 | Semaglutide in medical therapy |
10 Oct, 2038
(13 years from now)
| Active |
| US10888605 | GLP-1 compositions and uses thereof |
24 Aug, 2038
(13 years from now)
| Active |
| US11752198 | GLP-1 compositions and uses thereof |
24 Aug, 2038
(13 years from now)
| Active |
| US12214017 | GLP-1 compositions and uses thereof |
24 Aug, 2038
(13 years from now)
| Active |
| US9764003 | Use of long-acting GLP-1 peptides |
21 Jun, 2033
(8 years from now)
| Active |
| US8129343 | Acylated GLP-1 compounds |
05 Dec, 2031
(6 years from now)
| Active |
| US8536122 | Acylated GLP-1 compounds |
20 Mar, 2026
(10 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Wegovy's drug page
11. Xultophy 100/3.6
Xultophy 100/3.6 is protected by 45 patents, out of which 16 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9132239
(Pediatric)
| Dial-down mechanism for wind-up pen |
01 Aug, 2032
(7 years from now)
| Active |
| US9132239 | Dial-down mechanism for wind-up pen |
01 Feb, 2032
(6 years from now)
| Active |
| US7615532
(Pediatric)
| Insulin derivatives |
28 Dec, 2029
(4 years from now)
| Active |
| US8937042
(Pediatric)
| Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide |
05 Nov, 2029
(4 years from now)
| Active |
| US7615532 | Insulin derivatives |
28 Jun, 2029
(4 years from now)
| Active |
| US8937042 | Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide |
05 May, 2029
(3 years from now)
| Active |
| US9457154
(Pediatric)
| Injection device with an end of dose feedback mechanism |
27 Mar, 2028
(2 years from now)
| Active |
| US9457154 | Injection device with an end of dose feedback mechanism |
27 Sep, 2027
(2 years from now)
| Active |
| US9687611
(Pediatric)
| Injection device with torsion spring and rotatable display |
27 Aug, 2027
(2 years from now)
| Active |
| US9687611 | Injection device with torsion spring and rotatable display |
27 Feb, 2027
(1 year, 9 months from now)
| Active |
| USRE46363
(Pediatric)
| Dial-down mechanism for wind-up pen |
03 Feb, 2027
(1 year, 8 months from now)
| Active |
| US10220155
(Pediatric)
| Syringe device with a dose limiting mechanism and an additional safety mechanism |
17 Jan, 2027
(1 year, 8 months from now)
| Active |
| US8920383
(Pediatric)
| Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
17 Jan, 2027
(1 year, 8 months from now)
| Active |
| US9775953
(Pediatric)
| Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
17 Jan, 2027
(1 year, 8 months from now)
| Active |
| US7686786 | Dial-down mechanism for wind-up pen |
03 Aug, 2026
(1 year, 2 months from now)
| Active |
| USRE46363 | Dial-down mechanism for wind-up pen |
03 Aug, 2026
(1 year, 2 months from now)
| Active |
| US9108002
(Pediatric)
| Automatic injection device with a top release mechanism |
20 Jul, 2026
(1 year, 2 months from now)
| Active |
| US9616180
(Pediatric)
| Automatic injection device with a top release mechanism |
20 Jul, 2026
(1 year, 2 months from now)
| Active |
| US9861757
(Pediatric)
| Injection device with an end of dose feedback mechanism |
20 Jul, 2026
(1 year, 2 months from now)
| Active |
| US10220155 | Syringe device with a dose limiting mechanism and an additional safety mechanism |
17 Jul, 2026
(1 year, 2 months from now)
| Active |
| US8920383 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
17 Jul, 2026
(1 year, 2 months from now)
| Active |
| US9775953 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
17 Jul, 2026
(1 year, 2 months from now)
| Active |
| US8684969
(Pediatric)
| Injection device with torsion spring and rotatable display |
20 Apr, 2026
(11 months from now)
| Active |
| US10357616 | Injection device with an end of dose feedback mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US10376652 | Automatic injection device with a top release mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US9108002 | Automatic injection device with a top release mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US9616180 | Automatic injection device with a top release mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US9861757 | Injection device with an end of dose feedback mechanism |
20 Jan, 2026
(8 months from now)
| Active |
| US8684969 | Injection device with torsion spring and rotatable display |
20 Oct, 2025
(5 months from now)
| Active |
| US7762994
(Pediatric)
| Needle mounting system and a method for mounting a needle assembly |
23 Nov, 2024
(5 months ago)
| Expired |
| US7762994 | Needle mounting system and a method for mounting a needle assembly |
23 May, 2024
(11 months ago)
| Expired |
| US8579869
(Pediatric)
| Needle mounting system and a method for mounting a needle assembly |
30 Dec, 2023
(1 year, 4 months ago)
| Expired |
| US8579869 | Needle mounting system and a method for mounting a needle assembly |
30 Jun, 2023
(1 year, 10 months ago)
| Expired |
| US6268343
(Pediatric)
| Derivatives of GLP-1 analogs |
22 Feb, 2023
(2 years ago)
| Expired |
| US8846618
(Pediatric)
| Stable formulation of modified GLP-1 |
27 Dec, 2022
(2 years ago)
| Expired |
| US6268343 | Derivatives of GLP-1 analogs |
22 Aug, 2022
(2 years ago)
| Expired |
| US6899699
(Pediatric)
| Automatic injection device with reset feature |
02 Jul, 2022
(2 years ago)
| Expired |
| US8672898
(Pediatric)
| Automatic injection device with reset feature |
02 Jul, 2022
(2 years ago)
| Expired |
| US9486588
(Pediatric)
| Automatic injection device with reset feature |
02 Jul, 2022
(2 years ago)
| Expired |
| US8846618 | Stable formulation of modified GLP-1 |
27 Jun, 2022
(2 years ago)
| Expired |
| US6899699 | Automatic injection device with reset feature |
02 Jan, 2022
(3 years ago)
| Expired |
| US8672898 | Automatic injection device with reset feature |
02 Jan, 2022
(3 years ago)
| Expired |
| US9486588 | Automatic injection device with reset feature |
02 Jan, 2022
(3 years ago)
| Expired |
| US6458924 | Derivatives of GLP-1 analogs |
22 Aug, 2017
(7 years ago)
| Expired |
| US7235627 | Derivatives of GLP-1 analogs |
22 Aug, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xultophy 100/3.6's drug page